Stockscreener 앱 받기
8.01
4.07%
-0.34
전일 마감가:
$8.35
열려 있는:
$8.7
하루 거래량:
69,153
Relative Volume:
0.92
시가총액:
$70.27M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-6.3071
EPS:
-1.27
순현금흐름:
$-117.73M
1주 성능:
-10.76%
1개월 성능:
-21.70%
6개월 성능:
-31.71%
1년 성능:
-59.85%
1일 변동 폭
$7.92
$8.70
1주일 범위
$7.611
$10.38
52주 변동 폭
$7.611
$25.50
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.05 | 70.27M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.53 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.62 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
623.27 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.81 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.90 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal year - Investing.com
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia
Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa
Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com
Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq
Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com
Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune
Karyopharm announces 1-for-15 reverse stock split - MSN
Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa
Can Karyopharm's 15:1 Reverse Split Save Its Nasdaq Listing? - StockTitan
Karyopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World
Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks
Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN
H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa
Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks
Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks
Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
H.C. Wainwright maintains Buy on Karyopharm with $7 target - Investing.com India
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript - Insider Monkey
Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance
Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding - TipRanks
Karyopharm Therapeutics: Q4 Earnings Snapshot - CT Insider
Earnings call transcript: Karyopharm Q4 2024 revenue misses forecasts By Investing.com - Investing.com Canada
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates - MSN
Earnings call transcript: Karyopharm Q4 2024 revenue misses forecasts - Investing.com India
Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Previ - GuruFocus.com
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress - Victoria Advocate
Karyopharm Therapeutics: Q4 Earnings Snapshot -February 19, 2025 at 07:46 am EST - Marketscreener.com
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Karyopharm Therapeutics' SWOT analysis: stock potential amid clinical trials - Investing.com India
Karyopharm Therapeutics' SWOT analysis: stock potential amid clinical trials By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200-Day Moving AverageWhat's Next? - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 - Citizentribune
Did Karyopharm Therapeutics Inc (KPTI) perform well in the last session? - US Post News
Karyopharm Therapeutics (NASDAQ:KPTI) Given “Outperform” Rating at Royal Bank of Canada - Defense World
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Shares Fall By 1.43 Percent In The Past Week, But How Long Will It Last? – Marketing Sentinel - Marketing Sentinel
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Karyopharm Therapeutics Inc 주식 (KPTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
Feb 04 '25 |
Sale |
0.65 |
4,099 |
2,664 |
1,120,158 |
| Paulson Richard A. | President and CEO |
Jan 06 '25 |
Sale |
0.78 |
4,055 |
3,175 |
1,124,257 |
| Paulson Richard A. | President and CEO |
Dec 04 '24 |
Sale |
0.81 |
3,620 |
2,932 |
1,128,312 |
| Paulson Richard A. | President and CEO |
Nov 05 '24 |
Sale |
0.91 |
3,675 |
3,346 |
1,131,932 |
| Paulson Richard A. | President and CEO |
Oct 04 '24 |
Sale |
0.88 |
3,607 |
3,172 |
1,135,607 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 04 '24 |
Sale |
0.72 |
3,971 |
2,866 |
273,881 |
| Paulson Richard A. | President and CEO |
Sep 04 '24 |
Sale |
0.72 |
3,667 |
2,647 |
1,139,214 |
| Mason Michael | EVP, CFO & Treasurer |
Sep 04 '24 |
Sale |
0.72 |
7,050 |
5,089 |
391,054 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 04 '24 |
Sale |
0.72 |
5,356 |
3,866 |
404,051 |
| Paulson Richard A. | President and CEO |
Aug 06 '24 |
Sale |
0.93 |
3,608 |
3,355 |
1,142,881 |
2.29%
0.57%
자본화:
|
볼륨(24시간):